ExpreS2ion publishes prospectus in connection with fully guaranteed rights issue of approximately SEK 73 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 13 April 2022 – The Board of Directors of ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”) announced on 6 April 2022, on the basis of the authorization from the Annual General Meeting on 26 May 2021,